JPET Assistant Professor of Medicine (Clinician-Educator)

Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
 QUICK SEARCH:   [advanced]


     


This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Hann, R. M.
Right arrow Articles by Eterovic, V. A.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Hann, R. M.
Right arrow Articles by Eterovic, V. A.

Vol. 287, Issue 1, 253-260, October 1998

Characterization of Cembranoid Interaction with the Nicotinic Acetylcholine Receptor1

Richard M. Hann , Oné R. Pagán , Liza Gregory, Tomas Jácome, Abimael D. Rodríguez , P. A. Ferchmin , Ruiliang Lu2 and Vesna A. Eterovic'

Department of Biochemistry (R.M.H., O.R.P., L.G., T.J., P.A.F., R.L., V.A.E.) and Center for Molecular and Behavioral Neuroscience (R.M.H., O.R.P., A.D.R., P.A.F., R.L., V.A.E.), Universidad Central del Caribe, Bayamón and Department of Chemistry (A.D.R.), University of Puerto Rico-Rio Piedras Campus, San Juan, Puerto Rico

The class of diterpenoids with a 14-carbon cembrane ring, the cembranoids, includes both competitive and noncompetitive inhibitors of the nicotinic acetylcholine receptor (AChR). All 20 coelenterate-derived cembranoids studied in this report inhibited [piperidyl-3,4-3H]-phencyclidine ([3H]-PCP) binding to its high-affinity site on the electric organ AChR, with IC50s ranging from 0.9 µM for methylpseudoplexaurate to 372 µM for lophotoxin. Inhibition was complete with all cembranoids but lophotoxin and most Hill coefficients were close to 1. Methylpseudoplexaurate and [3H]-PCP binding was competitive. Methylpseudoplexaurate and the fourth most potent cembranoid, eunicin, competed with each other for [3H]-PCP displacement, indicating that there exist one or more cembranoid sites on the AChR. Cembranoid affinity for the AChR correlated with hydrophobicity, but was also dependent on other features. Methylpseudoplexaurate and n-octanol also competed with each other for [3H]-PCP displacement, indicating that the cembranoid site is linked to the n-octanol site on the AChR. Unlike lophotoxin, the five cembranoids tested did not inhibit [125I]Tyr54-alpha -bungarotoxin binding to the AChR agonist sites. All seven cembranoids tested on oocyte-expressed electric organ AChR reversibly blocked acetylcholine-induced currents, although the inhibitor concentration curves were shallow and the inhibition was incomplete.


0022-3565/98/2871-0253$03.00/0
THE JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS
Copyright © 1998 by The American Society for Pharmacology and Experimental Therapeutics



This article has been cited by other articles:


Home page
BloodHome page
H. Matsushima, H. Tanaka, N. Mizumoto, and A. Takashima
Identification of crassin acetate as a new immunosuppressant triggering heme oxygenase-1 expression in dendritic cells
Blood, July 2, 2009; 114(1): 64 - 73.
[Abstract] [Full Text] [PDF]


Home page
Proc. Natl. Acad. Sci. USAHome page
H. Ulrich, J. E. Ippolito, O. R. Pagan, V. A. Eterovic, R. M. Hann, H. Shi, J. T. Lis, M. E. Eldefrawi, and G. P. Hess
In vitro selection of RNA molecules that displace cocaine from the membrane-bound nicotinic acetylcholine receptor
PNAS, November 24, 1998; 95(24): 14051 - 14056.
[Abstract] [Full Text] [PDF]




Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
All ASPET Journals Molecular Pharmacology Pharmacological Reviews
 Molecular Interventions Drug Metabolism and Disposition

Copyright © 1998 by the American Society for Pharmacology and Experimental Therapeutics.